Proposal to expand the Genovis Board of Directors at 2018 Annual General Meeting

The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2018 Annual General Meeting. Under the proposal two directors, Lena Söderström and Peter Hein, will be elected, while Jacob Engellau will leave the Board.

Lena Söderström has been CEO of Senzime AB (publ) since 2013 and was previously CEO of Isconova and Kibion; prior to that she held various positions at Fresenius Kabi and Pharmacia. Lena has extensive Board experience and is currently on the Board of Directors of Uppsala University Holding AB and SLU Holding AB.

Peter Hein has extensive experience from leading positions in the life science industry. He has been CFO at Q-Med and Biolipox (Orexo). He has also served as CFO and CEO of Granngården. His background is in business and finance, including at Ericsson and Swedish Match in Switzerland. For the past two years Peter has worked as a consultant and interim CFO for a couple of small biotech companies.

“We are extremely pleased to be able to bring in two such experienced and knowledgeable individuals to the Genovis Board of Directors. The company is currently in a growth phase with an expanded geographic presence and a strong dynamic product portfolio. We consider this proposal to the AGM of two such talented candidates with new skills to be extremely valuable,” says Mikael Lönn, chairman of the Nomination Committee.

The new Board of Directors in the proposal to the AGM is as follows: re-election of Mårten Winge, Lena Mårtensson Wernrud, Kenth Petersson and Mikael Lönn, and election of Lena Söderström and Peter Hein.

The Nomination Committee proposes re-election of Mårten Winge to serve as Chairman of the Board.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233


Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser. T: +46 (0)8-463 83 00.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North


Documents & Links